《大行報告》富瑞:仍對藥明生物(02269.HK)有很高信心 股價調整爲吸納黃金機會
富瑞表示,相信藥明生物(02269.HK)有能力且會解決子公司無錫藥明生物及上海藥明生物列入未經覈實名單(UVL)的問題,仍然對藥明生物充滿信心,這兩日股價下跌是吸納的黃金機會,建議在接下來的幾天內收集。該行重申藥明生物「買入」評級,目標價200元。
富瑞指出,被列入UVL可能是由於採購物料最終用途審查未得到滿足,若公司進行了更正,包括提交的書面證據,則可以將公司從UVL中剔除。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.